107 related articles for article (PubMed ID: 27924500)
1. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Hu FY; Cao XN; Xu QZ; Deng Y; Lai SY; Ma J; Hu JB
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):839-845. PubMed ID: 27924500
[TBL] [Abstract][Full Text] [Related]
2. Cytosolic malic enzyme and glucose-6-phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance.
Ran M; Zhou Y; Guo Y; Huang D; Zhang SL; Tam KY
FEBS J; 2023 Oct; 290(19):4792-4809. PubMed ID: 37410361
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of miR-578 through SOCS2-dependent manner reverses gefitinib resistance in NSCLC cells.
Yang B; Yao L; Yang L; Zhao F; Zhou W
Environ Toxicol; 2024 Mar; 39(3):1283-1293. PubMed ID: 37948135
[TBL] [Abstract][Full Text] [Related]
4. Measuring competitive exclusion in non-small cell lung cancer.
Farrokhian N; Maltas J; Dinh M; Durmaz A; Ellsworth P; Hitomi M; McClure E; Marusyk A; Kaznatcheev A; Scott JG
Sci Adv; 2022 Jul; 8(26):eabm7212. PubMed ID: 35776787
[TBL] [Abstract][Full Text] [Related]
5. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
6. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients.
Chandra F; Sandiono D; Sugiri U; Suwarsa O; Gunawan H
Dermatol Ther (Heidelb); 2017 Mar; 7(1):133-141. PubMed ID: 28004308
[TBL] [Abstract][Full Text] [Related]
8. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase 3 Inhibition Overcomes
Tanimoto A; Takeuchi S; Arai S; Fukuda K; Yamada T; Roca X; Ong ST; Yano S
Clin Cancer Res; 2017 Jun; 23(12):3139-3149. PubMed ID: 27986747
[No Abstract] [Full Text] [Related]
10. Focus on Alectinib and Competitor Compounds for Second-Line Therapy in
Tran PN; Klempner SJ
Front Med (Lausanne); 2016; 3():65. PubMed ID: 27965961
[TBL] [Abstract][Full Text] [Related]
11. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY
Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177
[TBL] [Abstract][Full Text] [Related]
12. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
[TBL] [Abstract][Full Text] [Related]
13. Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report.
Li L; Wang H; Li C; Wang Z; Zhang P; Yan X
Oncotarget; 2017 Mar; 8(11):18609-18614. PubMed ID: 28061471
[TBL] [Abstract][Full Text] [Related]
14. Outcome of EGFR inhibitors treatment in advanced NSCLC patients, not enrolled in clinical trials.
Mencoboni M; Filiberti RA; Taveggia P; Bruzzone A; Garuti A; Del Corso L; Ginocchio E; Brianti A; Simonassi C; Zucali P
Neoplasma; 2017; 64(2):253-261. PubMed ID: 28043153
[TBL] [Abstract][Full Text] [Related]
15. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
Kalu NN; Johnson FM
Expert Opin Investig Drugs; 2017 Feb; 26(2):207-217. PubMed ID: 28042706
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
[TBL] [Abstract][Full Text] [Related]
17. Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor.
Fujita K; Kim YH; Yoshizawa A; Mio T; Mishima M
Respirol Case Rep; 2017 Jan; 5(1):e00206. PubMed ID: 28031840
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of afatinib in lung cancer with paralytic ileus due to peritoneal carcinomatosis.
Kobayashi H; Wakuda K; Takahashi T
Respirol Case Rep; 2016 Nov; 4(6):e00197. PubMed ID: 28031832
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
[TBL] [Abstract][Full Text] [Related]
20. Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.
Han K; Chanu P; Jonsson F; Winter H; Bruno R; Jin J; Stroh M
AAPS J; 2017 Mar; 19(2):527-533. PubMed ID: 28028730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
